China’s NMPA approves GSK’s Nucala for CRSwNP treatment
The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with ...
Daily4d
GSK Nucala approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps
London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a ...
Pharmabiz5d
GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps
GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Saturday, January 4, 2025, 09:00 Hrs [IST] GSK plc announced ...
MARKET REPORT: Airlines lose altitude as higher fuel costs bite
EasyJet was a big FTSE 100 faller, down 3.1 per cent, or 17p, to 540.4p and British Airways owner IAG - a top blue-chip ...
FiercePharma5d
Regulatory tracker: Agios' Pyrukynd gets updated liver injury warning on its label
Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...
Hosted on MSN5d
European Equities Close Mostly Lower in Friday Trading; German Employment Rises For Second Straight Month
The European stock markets closed mostly lower in Friday trading as The Stoxx Europe fell 0.49%, Germany's DAX dropped 0.58%, the FTSE in London was down 0.44%, France's CAC shed 1.51%, while the ...
The Pharma Letter5d
GSK’s Nucala wins wider approval in China
China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...
GSK gets approval in China for Nucala for rhinosinusitis
GSK (NYSE:GSK) has received Chinese regulatory approval for its drug Nucala, also known as mepolizumab, for the treatment of ...
ENDPOINTS NEWS5d
GSK’s Nu­cala bags an­oth­er Chi­na ap­proval, but biggest test yet to come
GSK's Nucala gets China approval for chronic rhinosinusitis with nasal polyps; awaits FDA decision for COPD in May as it ...
GSK's Sinus Disease Drug Secures Approval In China
On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on ...
GSK’s Nucala approved in China as add-on therapy for adults with CRSwNP
GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that targets ...
GSK's Nucala gets third approval in China
GSK announced on Friday that its monoclonal antibody ‘Nucala’, or mepolizumab, has received approval from China's National ...